Raymond J. Guidotti
Directeur des opérations chez ApiJect Systems Corp.
Profil
Raymond J.
Guidotti is currently the Chief Operating Officer at ApiJect Systems Corp.
Postes actifs de Raymond J. Guidotti
| Sociétés | Poste | Début |
|---|---|---|
ApiJect Systems Corp.
 ApiJect Systems Corp. Information Technology ServicesTechnology Services ApiJect Systems Corp. is a medical technology company that specializes in manufacturing and delivering injectable medicines and vaccines. ApiJect is based in Stamford, CT, and has subsidiaries in the United States. The private company's technology platform uses a blow-fill-seal (BFS) fill-finish process to create scalable drug delivery devices that can be produced in clinical or commercial scale. ApiJect's first device, the single-dose ApiJect prefilled injector, is a simple and scalable prefilled syringe that is being tested and reviewed for COVID-19 vaccines. The company has been awarded a $138 million contract from the U.S. Department of Defense to create a high-volume domestic capacity to supply prefilled injectors. Additionally, ApiJect has been approved for a $590 million loan to construct a multi-facility campus in Research Triangle Park, NC, which will be home to the ApiJect gigafactory, one of the world's largest pharmaceutical fill-finish facilities. The company is dedicated to making injectable medicines safe and available for everyone. The company was founded in 2015 by Marc Koska. | Directeur des opérations | 01/03/2021 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
ApiJect Systems Corp.
ApiJect Systems Corp. Information Technology ServicesTechnology Services ApiJect Systems Corp. is a medical technology company that specializes in manufacturing and delivering injectable medicines and vaccines. ApiJect is based in Stamford, CT, and has subsidiaries in the United States. The private company's technology platform uses a blow-fill-seal (BFS) fill-finish process to create scalable drug delivery devices that can be produced in clinical or commercial scale. ApiJect's first device, the single-dose ApiJect prefilled injector, is a simple and scalable prefilled syringe that is being tested and reviewed for COVID-19 vaccines. The company has been awarded a $138 million contract from the U.S. Department of Defense to create a high-volume domestic capacity to supply prefilled injectors. Additionally, ApiJect has been approved for a $590 million loan to construct a multi-facility campus in Research Triangle Park, NC, which will be home to the ApiJect gigafactory, one of the world's largest pharmaceutical fill-finish facilities. The company is dedicated to making injectable medicines safe and available for everyone. The company was founded in 2015 by Marc Koska. | Technology Services |
